VERTEX PHARMACEUTICALS INC / MA
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $12.0 | $11.0 | $9.9 | $8.9 | $7.6 |
| Operating income | $4.2 | -$0.2 | $3.8 | $4.3 | $2.8 |
| Net income | $4.0 | -$0.5 | $3.6 | $3.3 | $2.3 |
| Cash Flow Statement | |||||
| Free cash flow | $3.2 | -$0.8 | $3.3 | $3.9 | $2.4 |
| Share repurchases | $2.0 | $1.2 | $0.4 | $0.0 | $1.4 |
Shares outstanding 253.5M · Free float 99.8%
Annual filing data through FY ended December 31, 2025; float as of September 21, 2026.